Free Trial

EyePoint Pharmaceuticals (EYPT) News Today

EyePoint Pharmaceuticals logo
$7.03 -0.27 (-3.64%)
As of 11:14 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
EyePoint Pharmaceuticals, Inc. stock logo
Susquehanna Fundamental Investments LLC Takes $922,000 Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Susquehanna Fundamental Investments LLC acquired a new position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 123,769 shares of the company's stock, valued at appr
EyePoint Pharmaceuticals, Inc. stock logo
EyePoint Pharmaceuticals (EYPT) Projected to Post Earnings on Wednesday
EyePoint Pharmaceuticals (NASDAQ:EYPT) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-7-eyepoint-pharmaceuticals-inc-stock/)
EyePoint Pharmaceuticals, Inc. stock logo
Ally Bridge Group NY LLC Makes New Investment in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Ally Bridge Group NY LLC acquired a new stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 348,000 shares of the company's stock, val
EyePoint Pharmaceuticals, Inc. stock logo
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Sold by Price T Rowe Associates Inc. MD
Price T Rowe Associates Inc. MD lowered its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 13.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,144,747 shares of the
EyePoint Pharmaceuticals, Inc. stock logo
Oracle Investment Management Inc. Sells 350,000 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Oracle Investment Management Inc. lessened its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 91.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 32,500 shares of the company's stock after selling 350,000 shares during
EyePoint Pharmaceuticals, Inc. stock logo
3,181,818 Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Purchased by RA Capital Management L.P.
RA Capital Management L.P. bought a new stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 3,181,818 shares of the company's stock, valued at approximately $23,705
EyePoint Pharmaceuticals, Inc. stock logo
Renaissance Technologies LLC Reduces Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Renaissance Technologies LLC lowered its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 26.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 137,500 shares
EyePoint Pharmaceuticals, Inc. stock logo
TCG Crossover Management LLC Acquires 2,650,000 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
TCG Crossover Management LLC raised its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 287.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,572,335 shares of the company's stock afte
EyePoint Pharmaceuticals, Inc. stock logo
Nantahala Capital Management LLC Buys New Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Nantahala Capital Management LLC bought a new stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 600,000 shares of the company's stock, valued at appr
EyePoint Pharmaceuticals, Inc. stock logo
T. Rowe Price Investment Management Inc. Sells 1,061,815 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
T. Rowe Price Investment Management Inc. trimmed its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 83.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 206,939 shares of the company's stock after selling 1,061,815 s
EyePoint Pharmaceuticals, Inc. stock logo
Artia Global Partners LP Has $1.61 Million Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Artia Global Partners LP grew its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 38.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 216,700 shares of the company's stock after purchasing an additional 60
EyePoint Pharmaceuticals, Inc. stock logo
Adage Capital Partners GP L.L.C. Boosts Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Adage Capital Partners GP L.L.C. boosted its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 51.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,750,000 shares of
EyePoint Pharmaceuticals, Inc. stock logo
Blue Owl Capital Holdings LP Invests $4.97 Million in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Blue Owl Capital Holdings LP acquired a new position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 667,594 shares of the company's stock, valued at approximately $
EyePoint Pharmaceuticals, Inc. stock logo
Geode Capital Management LLC Has $11.47 Million Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Geode Capital Management LLC grew its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 28.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,538,902 shares of the company's stock after purchasing an additiona
EyePoint Pharmaceuticals, Inc. stock logo
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Recommendation of "Buy" from Analysts
Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have earned a consensus rating of "Buy" from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Nine research analysts have rated the stock with a buy rating. The average twelve-month pr
EyePoint Pharmaceuticals, Inc. stock logo
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) is Essex Woodlands Management Inc.'s 4th Largest Position
Essex Woodlands Management Inc. lessened its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 24.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,169,857 shares of the company's stock after selling 381,664 shares during
EyePoint Pharmaceuticals, Inc. stock logo
Vanguard Group Inc. Purchases 755,045 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Vanguard Group Inc. increased its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 24.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,803,227 shares of the company's stock after acquir
EyePoint Pharmaceuticals, Inc. stock logo
Federated Hermes Inc. Increases Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Federated Hermes Inc. increased its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 92.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,707,445 shares of the company's stock after acquiring
EyePoint Pharmaceuticals, Inc. stock logo
Finepoint Capital LP Grows Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Finepoint Capital LP boosted its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 57.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,111,104 shares of the company's stock a
EyePoint Pharmaceuticals, Inc. stock logo
Schroder Investment Management Group Purchases 146,403 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Schroder Investment Management Group raised its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 118.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 270,336 shares of the company
EyePoint Pharmaceuticals, Inc. stock logo
Franklin Resources Inc. Purchases 125,519 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Franklin Resources Inc. lifted its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 3.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,137,567 shares of the company's stock after purchasing an additional 1
EyePoint Pharmaceuticals, Inc. stock logo
Charles Schwab Investment Management Inc. Purchases 48,402 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Charles Schwab Investment Management Inc. boosted its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 33.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 191,165 shares of the compan
EyePoint Pharmaceuticals, Inc. stock logo
What is Chardan Capital's Estimate for EYPT FY2025 Earnings?
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Research analysts at Chardan Capital issued their FY2025 EPS estimates for shares of EyePoint Pharmaceuticals in a research report issued to clients and investors on Monday, March 24th. Chardan Capital analyst D. Gataulin forecasts that
EyePoint Pharmaceuticals, Inc. stock logo
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of "Buy" from Analysts
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has been assigned a consensus recommendation of "Buy" from the nine analysts that are presently covering the firm, MarketBeat reports. Nine research analysts have rated the stock with a buy recommendation. The average twelve-month pric
EyePoint Pharmaceuticals, Inc. stock logo
What is Chardan Capital's Forecast for EYPT FY2026 Earnings?
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Chardan Capital issued their FY2026 EPS estimates for EyePoint Pharmaceuticals in a report issued on Monday, March 24th. Chardan Capital analyst D. Gataulin anticipates that the company will post earnings per share of ($2.82) for the ye
EyePoint Pharmaceuticals, Inc. stock logo
Erste Asset Management GmbH Invests $360,000 in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Erste Asset Management GmbH bought a new position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 50,000 shares of the company's stock, valued at app
EyePoint Pharmaceuticals, Inc. stock logo
StockNews.com Upgrades EyePoint Pharmaceuticals (NASDAQ:EYPT) to "Sell"
StockNews.com upgraded shares of EyePoint Pharmaceuticals to a "sell" rating in a report on Friday.
EyePoint Pharmaceuticals, Inc. stock logo
Research Analysts Set Expectations for EYPT FY2025 Earnings
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for EyePoint Pharmaceuticals in a research report issued on Thursday, March 6th. Cantor Fitzgerald analyst J. Kim now expects that the company will post earnings per shar
EyePoint Pharmaceuticals, Inc. stock logo
Q1 EPS Estimate for EyePoint Pharmaceuticals Cut by Analyst
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Equities research analysts at HC Wainwright cut their Q1 2025 earnings per share estimates for shares of EyePoint Pharmaceuticals in a report released on Thursday, March 6th. HC Wainwright analyst Y. Chen now anticipates that the compan
EyePoint Pharmaceuticals, Inc. stock logo
EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 7.4% - Here's What Happened
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 7.4% - Here's What Happened
JonesTrading Remains a Buy on EyePoint Pharmaceuticals (EYPT)
EyePoint Pharmaceuticals, Inc. stock logo
EyePoint Pharmaceuticals (NASDAQ:EYPT) Receives Buy Rating from Chardan Capital
Chardan Capital reissued a "buy" rating and issued a $33.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday.
EyePoint Pharmaceuticals, Inc. stock logo
EyePoint Pharmaceuticals (NASDAQ:EYPT) Earns "Buy" Rating from HC Wainwright
HC Wainwright reissued a "buy" rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday.
EyePoint Pharmaceuticals, Inc. stock logo
EyePoint Pharmaceuticals (NASDAQ:EYPT) Releases Earnings Results, Misses Estimates By $0.10 EPS
EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%.
EyePoint Pharmaceuticals, Inc. stock logo
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of "Buy" from Brokerages
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has been assigned an average rating of "Buy" from the nine analysts that are presently covering the company, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating. The average 12-month price
EyePoint Pharmaceuticals, Inc. stock logo
Levin Capital Strategies L.P. Purchases 44,000 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Levin Capital Strategies L.P. increased its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 440.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 54,000 shares of the company's stock afte
EyePoint Pharmaceuticals, Inc. stock logo
EyePoint Pharmaceuticals (EYPT) Projected to Post Quarterly Earnings on Thursday
EyePoint Pharmaceuticals (NASDAQ:EYPT) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=670489)
Get EyePoint Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.

EYPT Media Mentions By Week

EYPT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

EYPT
News Sentiment

1.37

0.73

Average
Medical
News Sentiment

EYPT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

EYPT Articles
This Week

12

4

EYPT Articles
Average Week

Get EyePoint Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:EYPT) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners